Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study
- PMID: 17617116
- DOI: 10.1111/j.1478-3231.2007.01522.x
Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study
Abstract
An 80% dysfunction rate at 2 years limits the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of complications of portal hypertension. The use of covered stents could improve shunt patency; however, long-term effect and safety remain unknown. Eighty patients randomized to be treated by TIPS either with a covered stent (Group 1) or an uncovered prosthesis (Group 2) were followed-up for 2 years. Doppler US was performed every 3 months. Angiography and portosystemic pressure gradient measurement were performed every 6 months or whenever dysfunction was suspected. Actuarial rates of primary patency in Groups 1 and 2 were 76% and 36% respectively (P=0.001). Clinical relapse occurred in four patients (10%) in Group 1 and 12 (29%) in Group 2 (P<0.05). Actuarial rates of being free of encephalopathy were 67% in Group 1 and 51% in Group 2 (P<0.05). Probability of survival was 58% and 45% at 2 years, respectively, in Groups 1 and 2 (NS). The mean Child-Pugh score improved only in Group 1 (from 8.1+/-1.6 to 7+/-2.2 at 2 years -P<0.05). We also compared the Doppler-US parameters between patent and dysfunctioning shunts. In patent shunts, the mean velocity within the portal vein was significantly higher but the performance of Doppler-US was not accurate enough to predict shunt dysfunction. In conclusion, the improvement in TIPS patency by using covered prostheses is maintained over time with a decreased risk of encephalopathy, while the risk of death was not increased.
Similar articles
-
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.World J Gastroenterol. 2014 Dec 7;20(45):16996-7010. doi: 10.3748/wjg.v20.i45.16996. World J Gastroenterol. 2014. PMID: 25493012 Free PMC article. Review.
-
Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.World J Gastroenterol. 2014 Jan 21;20(3):774-85. doi: 10.3748/wjg.v20.i3.774. World J Gastroenterol. 2014. PMID: 24574750 Free PMC article.
-
Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.J Vasc Interv Radiol. 2004 Mar;15(3):239-48. doi: 10.1097/01.rvi.0000116194.44877.c1. J Vasc Interv Radiol. 2004. PMID: 15028808
-
Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts.World J Gastroenterol. 2015 Jul 14;21(26):8110-7. doi: 10.3748/wjg.v21.i26.8110. World J Gastroenterol. 2015. PMID: 26185383 Free PMC article.
-
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S344-51. doi: 10.1097/MCG.0b013e318157e500. J Clin Gastroenterol. 2007. PMID: 17975487 Review.
Cited by
-
Recent developments in the management of ascites in cirrhosis.United European Gastroenterol J. 2024 Mar;12(2):261-272. doi: 10.1002/ueg2.12539. Epub 2024 Feb 10. United European Gastroenterol J. 2024. PMID: 38340308 Free PMC article. Review.
-
Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.United European Gastroenterol J. 2023 Oct;11(8):733-744. doi: 10.1002/ueg2.12454. Epub 2023 Sep 22. United European Gastroenterol J. 2023. PMID: 37736854 Free PMC article.
-
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.World J Gastroenterol. 2014 Dec 7;20(45):16996-7010. doi: 10.3748/wjg.v20.i45.16996. World J Gastroenterol. 2014. PMID: 25493012 Free PMC article. Review.
-
Step by Step: Managing the Complications of Cirrhosis.Hepat Med. 2021 May 25;13:45-57. doi: 10.2147/HMER.S278032. eCollection 2021. Hepat Med. 2021. PMID: 34079394 Free PMC article. Review.
-
Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt.World J Hepatol. 2013 Jan 27;5(1):38-42. doi: 10.4254/wjh.v5.i1.38. World J Hepatol. 2013. PMID: 23383365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous